$DARE
Dare Bioscience, Inc. Stock $dare

$dare Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000140191423000023 Filed on May 11, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$0.00	$0.00
YoY Change	-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.946M	$3.362M
YoY Change	4.53%	29.57%
% of Gross Profit
Research & Development	$6.044M	$5.020M
YoY Change	-11.09%	-13.53%
% of Gross Profit
Depreciation & Amortization	$9.610K	$9.508K
YoY Change	80.64%	81.9%
% of Gross Profit
Operating Expenses	$8.989M	$8.383M
YoY Change	-6.51%	-0.21%
Operating Profit	-$8.989M	-$8.383M
YoY Change	-2439.02%	-0.21%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$227.1K	$340.1K
YoY Change	665.24%	19020.18%
Pretax Income	-$8.762M	-$8.043M
YoY Change	-2216.48%	-4.24%
Income Tax
% Of Pretax Income
Net Earnings	-$8.762M	-$8.000M
YoY Change	-2216.48%	-4.76%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.10	-$0.09
Diluted Earnings Per Share	-$0.10	-$0.09
COMMON SHARES
Basic Shares Outstanding	86.28M shares	86.18M shares
Diluted Shares Outstanding	86.40M shares	85.52M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.33M	$19.83M
YoY Change	-58.44%	-49.57%
Cash & Equivalents	$13.30M	$19.83M
Short-Term Investments
Other Short-Term Assets	$272.1K	$201.4K
YoY Change	-95.39%	-97.03%
Inventory
Prepaid Expenses	$8.070M	$7.082M
Receivables
Other Receivables	$572.5K	$2.399M
Total Short-Term Assets	$22.24M	$29.51M
YoY Change	-55.61%	-38.28%
LONG-TERM ASSETS
Property, Plant & Equipment	$45.79K	$55.40K
YoY Change	-95.92%	118.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$920.9K	$799.3K
YoY Change	472.51%	-40.53%
Total Long-Term Assets	$966.7K	$854.7K
YoY Change	-24.58%	-37.58%
TOTAL ASSETS
Total Short-Term Assets	$22.24M	$29.51M
Total Long-Term Assets	$966.7K	$854.7K
Total Assets	$23.21M	$30.37M
YoY Change	-54.84%	-38.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.541M	$2.696M
YoY Change	487.05%	-4.78%
Accrued Expenses	$4.194M	$5.480M
YoY Change	-37.14%	54.9%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$24.70M	$24.34M
YoY Change	49.37%	48.45%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.229M	$1.057M
YoY Change	-32.64%	-44.74%
Total Long-Term Liabilities	$1.229M	$1.057M
YoY Change	-32.64%	-44.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.70M	$24.34M
Total Long-Term Liabilities	$1.229M	$1.057M
Total Liabilities	$25.93M	$25.40M
YoY Change	41.22%	38.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$157.9M	-$149.1M
YoY Change		25.82%
Common Stock	$155.6M	$154.5M
YoY Change		3.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.719M	$4.972M
YoY Change
Total Liabilities & Shareholders Equity	$23.21M	$30.37M
YoY Change	-54.84%	-38.26%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$8.762M	-$8.000M
YoY Change	-2216.48%	-4.76%
Depreciation, Depletion And Amortization	$9.610K	$9.508K
YoY Change	80.64%	81.9%
Cash From Operating Activities	-$6.586M	-$16.12M
YoY Change	-22.04%	30.58%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00
YoY Change	-100.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	452.2K	$1.299M
YoY Change	-66.23%
NET CHANGE
Cash From Operating Activities	-6.586M	-$16.12M
Cash From Investing Activities	0.000	$0.00
Cash From Financing Activities	452.2K	$1.299M
Net Change In Cash	-6.134M	-$14.84M
YoY Change	-13.73%	20.09%
FREE CASH FLOW
Cash From Operating Activities	-$6.586M	-$16.12M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$6.586M	-$16.12M
YoY Change	-22.03%	30.53%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001401914
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-36395
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	DARÉ BIOSCIENCE, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-4139823
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3655 Nobel Drive
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 260
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	City Area Code CityAreaCode	858
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	926-7655
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92122
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock
CY2023Q1	dei	Trading Symbol TradingSymbol	DARE
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	86284827	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19829404	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34669605	usd
CY2023Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	2398708	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1703160	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7082452	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6665988	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	201385	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	0	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	29511949	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	43038753	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	55400	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	64908	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	799327	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	722722	usd
CY2023Q1	us-gaap	Assets Assets	30366676	usd
CY2022Q4	us-gaap	Assets Assets	43826383	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2695612	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2027953	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5480203	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10894016	usd
CY2023Q1	dare	Deferred Grant Funding Current DeferredGrantFundingCurrent	15826369	usd
CY2022Q4	dare	Deferred Grant Funding Current DeferredGrantFundingCurrent	18303567	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	335764	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	398391	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	24337948	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31623927	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1000000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1000000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	57128	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	90346	usd
CY2023Q1	us-gaap	Liabilities Liabilities	25395076	usd
CY2022Q4	us-gaap	Liabilities Liabilities	32714273	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-149117141	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	240000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	240000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86178996	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86178996	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	84825481	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	84825481	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	8618	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	8482	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-373316	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-351311	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	154453439	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	152529579	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-141074640	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	4971600	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11112110	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30366676	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	43826383	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3337426	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2569987	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5020223	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5805462	usd
CY2023Q1	dare	License Fee Expense LicenseFeeExpense	25000	usd
CY2022Q1	dare	License Fee Expense LicenseFeeExpense	25000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	8382649	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	8400449	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8382649	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8400449	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	340148	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1779	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-8042501	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-8398670	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8042501	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8398670	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-22005	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-9150	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8064506	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8407820	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	85517540	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	85517540	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	83944119	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	83944119	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11112110	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	624621	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1299375	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-8042501	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-22005	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	4971600	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	38754321	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	532409	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-8398670	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-9150	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	30878910	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-8042501	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-8398670	usd
CY2023Q1	us-gaap	Depreciation Depreciation	9508	usd
CY2022Q1	us-gaap	Depreciation Depreciation	5227	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	624621	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	532409	usd
CY2023Q1	dare	Non Cash Lease Expense NonCashLeaseExpense	-5906	usd
CY2022Q1	dare	Non Cash Lease Expense NonCashLeaseExpense	-9758	usd
CY2023Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	695548	usd
CY2022Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	584534	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	416464	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	4293814	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	201385	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	166545	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-87891	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	667661	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	727783	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-5413814	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	401613	usd
CY2023Q1	dare	Increase Decrease In Deferred Grant Funding IncreaseDecreaseInDeferredGrantFunding	2477198	usd
CY2022Q1	dare	Increase Decrease In Deferred Grant Funding IncreaseDecreaseInDeferredGrantFunding	811620	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16117571	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12343473	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4553	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4553	usd
CY2023Q1	dare	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	1299375	usd
CY2022Q1	dare	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1299375	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-22005	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-9150	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14840201	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12357176	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34669605	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51674087	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19829404	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39316911	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1043590	usd
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	35000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-149100000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19800000	usd
CY2023Q1	dare	Deferred Grant Funding Current DeferredGrantFundingCurrent	15800000	usd
CY2023Q1	dare	Working Capital Increase Deficit WorkingCapitalIncreaseDeficit	5200000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-8000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-16100000	usd
CY2023Q1	dare	Periodof Insufficient Cashand Liquidity Requirements PeriodofInsufficientCashandLiquidityRequirements	P12M
CY2018Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.00
CY2019Q2	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.98
CY2020Q3	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.96
CY2023Q1	dare	Number Of Common Stock Warrants Exercised NumberOfCommonStockWarrantsExercised	1353515	shares
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1300000	usd
CY2022Q1	dare	Number Of Common Stock Warrants Exercised NumberOfCommonStockWarrantsExercised	0	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6500	shares
CY2023Q1	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	5900000	usd
CY2023Q1	dare	Weighted Average Amortization Period WeightedAverageAmortizationPeriod	P2Y8M15D
CY2018Q3	us-gaap	Net Rentable Area NetRentableArea	3169	sqft
CY2022Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P2Y
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-504000	usd
CY2022	dare	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-458000	usd
CY2022	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	46000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	368000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	336000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	57000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	139000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	169000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	105000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	123000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y29D
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	317000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	93000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	410000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	17000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	393000	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9116719	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7658297	shares

Files In Submission

Name	View Source	Status
dare-20230331_cal.xml	Edgar Link	unprocessable
dare-20230331_lab.xml	Edgar Link	unprocessable
dare-20230331_def.xml	Edgar Link	unprocessable
0001401914-23-000023-index-headers.html	Edgar Link	pending
0001401914-23-000023-index.html	Edgar Link	pending
0001401914-23-000023.txt	Edgar Link	pending
0001401914-23-000023-xbrl.zip	Edgar Link	pending
dare-20230331.htm	Edgar Link	pending
dare-20230331.xsd	Edgar Link	pending
dare-20230331_g1.jpg	Edgar Link	pending
exhibit311_20230331.htm	Edgar Link	pending
exhibit312_20230331.htm	Edgar Link	pending
exhibit321_20230331.htm	Edgar Link	pending
exhibit322_20230331.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
dare-20230331_pre.xml	Edgar Link	unprocessable
dare-20230331_htm.xml	Edgar Link	completed
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DARE
Dare Bioscience, Inc. Stock $dare

2023 Q2 Form 10-Q Financial Statement

#000140191423000023 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DARE Dare Bioscience, Inc. Stock $dare

2023 Q2 Form 10-Q Financial Statement

#000140191423000023 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DARE
Dare Bioscience, Inc. Stock $dare